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therapy: preclinical comparison of
161Tb-folate and 177Lu-folate
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Abstract
Background: The radiolanthanide 161Tb has, in recent years, attracted increasing interest due to its favorable
characteristics for medical application. 161Tb exhibits similar properties to the widely-used therapeutic radionuclide
177Lu. In contrast to 177Lu, 161Tb yields a significant number of short-ranging Auger/conversion electrons
(≤50 keV) during its decay process. 161Tb has been shown to be more effective for tumor therapy than
177Lu if applied using the same activity. The purpose of this study was to investigate long-term damage to
the kidneys after application of 161Tb-folate and compare it to the renal effects caused by 177Lu-folate.
Methods: Renal side effects were investigated in nude mice after the application of different activities of 161Tb-folate
(10, 20, and 30 MBq per mouse) over a period of 8 months. Renal function was monitored by the determination
of 99mTc-DMSA uptake in the kidneys and by measuring blood urea nitrogen and creatinine levels in the
plasma. Histopathological analysis was performed by scoring of the tissue damage observed in HE-stained
kidney sections from euthanized mice.
Results: Due to the co-emitted Auger/conversion electrons, the mean absorbed renal dose of 161Tb-folate
(3.0 Gy/MBq) was about 24 % higher than that of 177Lu-folate (2.3 Gy/MBq). After application of 161Tb-folate,
kidney function was reduced in a dose- and time-dependent manner, as indicated by the decreased renal
uptake of 99mTc-DMSA and the increased levels of blood urea nitrogen and creatinine. Similar results were
obtained when 177Lu-folate was applied at the same activity. Histopathological investigations confirmed comparable
renal cortical damage after application of the same activities of 161Tb-folate and 177Lu-folate. This was characterized by
collapsed tubules and enlarged glomeruli with fibrin deposition in moderately injured kidneys and glomerulosclerosis
in severely damaged kidneys.
Conclusions: Tb-folate induced dose-dependent radionephropathy over time, but did not result in more severe
damage than 177Lu-folate when applied at the same activity. These data are an indication that Auger/conversion
electrons do not exacerbate overall renal damage after application with 161Tb-folate as compared to 177Lu-folate,
even though they result in an increased dose deposition in the renal tissue. Global toxicity affecting other tissues
than kidneys remains to be investigated after 161Tb-based therapy, however.
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Background
The radiolanthanide terbium-161 (161Tb) has garnered
increasing interest in recent years due to its favorable
properties for medical application [1]. 161Tb has similar
chemical properties to the clinically established
lutetium-177 (177Lu), which enables stable coordination
using a DOTA-chelator and, consequently, its applica-
tion with well-established targeting agents [2]. The phys-
ical properties of 161Tb are also similar to those of 177Lu
(T1/2 = 6.7 d, Eβ
−
av = 134 keV, linear energy transfer (LET)
of about 0.34 keV/μm [3]). 161Tb decays, with a half-life
of 6.9 days, by the emission of low-energy β−-particles
(Eβ−av = 154 keV [3]) with a maximal tissue range of
0.29 mm and a LET of around 0.32 keV/μm, which is
suitable for the treatment of metastasized malignancies.
Importantly, 161Tb exhibits a co-emission of γ-radiation,
enabling imaging using single photon emission computed
tomography (SPECT) (Table 1). The decay process of
161Tb also releases a significant number of Auger/conver-
sion electrons of an energy ≤50 keV (~12.4 e−, 46.5 keV
per decay) [4], which are postulated to contribute to thera-
peutic anti-tumor effects [2]. This may be an advantage
over 177Lu which emits a negligible number of Auger/
conversion electrons in comparison (~1.11 e−, 1.0 keV
per decay, Table 1) [4]. High-energy electrons emitted
during β−-decay have a LET of about 0.2 keV/μm and a
tissue range of 0.5–12 mm, suitable for larger metasta-
ses [5]. The high LET (~4–26 keV/μm) and short tissue
range (~2–500 nm) of Auger/conversion electrons may
be of particular value for the treatment of single tumor
cells or tumor cell clusters [5]. This assumption has
been corroborated by dosimetric calculations published
by Uusijärvi et al., which clearly indicate the superiority
of 161Tb over 177Lu for the treatment of small lesions
(<200 μm) [6].
Another advantage of 161Tb may be the fact that other
Tb nuclides exist that emit diagnostic radiation only,
potentially allowing pre-therapeutic dosimetry and moni-
toring therapy response with chemically identical imaging
agents using SPECT (155Tb) and positron emission tom-
ography (PET) (152Tb) [7].
The few studies in which 161Tb was applied thus far,
focused on basic in vivo behavior of 161Tb-labeled bio-
molecules [8] and their effects on the malignant tissue
in comparison to 177Lu [2, 9]. These preliminary therapy
studies revealed that the therapeutic effect of 161Tb-
labeled compounds was superior to the effect of
their 177Lu-labeled counterparts, if applied at the
same activities as indicated by dosimetric calcula-
tions [2].
Potential differences between undesired side effects
of 161Tb and 177Lu have not been elucidated, how-
ever. The most critical organs in terms of side effects
after radionuclide therapy are the bone marrow, pop-
ulated by the highly radiosensitive hematopoietic cells,
and the kidneys, which accumulate radioactivity of
small molecular weight targeting agent at a high
extent [10]. In the present study, we focused on the
investigation of renal damage after exposure to thera-
peutic doses of 161Tb and 177Lu using a folate-based
small molecular targeting agent.
The folate receptor (FR) has been found expressed in a
wide variety of different tumor types, including cancer
of the ovaries, endometrium, lungs, and kidneys [11]. It
has therefore been exploited (pre)clinically for targeting
with folate-based radioconjugates for nuclear imaging
purposes [12, 13]. Following receptor binding on the cell
surface, folic acid and its conjugates are internalized via
FR-mediated endocytosis [14, 15]. This uptake mechan-
ism makes folic acid also attractive for FR-targeted
chemotherapy [16]. Recently, FR-targeted radionuclide
therapy was exemplified using a DOTA-folate conjugate
which was labeled with 177Lu [17]. It was shown that the
application of ≥20 MBq of 177Lu-folate resulted in
complete tumor remission in mice bearing KB tumor
xenografts.
Targeted tumor therapy with folic acid-based radio-
conjugates is, however, known to present a risk of dam-
age to the kidneys, since radiofolates accumulate
specifically in the proximal tubule cells where the FR is
expressed [11, 18]. This topic has been addressed
recently, in a detailed investigation of radionephropathy
after administration of 177Lu-folates with different in
vivo distribution profiles [19].
The purpose of the current long-term study was to
explore undesired side effects to the kidneys of mice
Table 1 Decay properties of 161Tb and 177Lu [3]
Radionuclide 161Tb 177Lu
Half-life 6.9 d 6.7 d
Eβ−av (intensity) 154 keV (1.00) 134 keV (1.00)
Eγ (intensity) 25.7 keV (0.23) 112.9 keV (0.062)
45 (0.18)* 208.4 keV (0.104)
48.9 keV (0.17)
74.6 keV (0.10)
E of Auger and conversion
electrons (intensity)
0–0.1 keV (0.72) 0–0.1 keV (0.27)
0.1–1 keV (7.38) 0.1–1 keV (0.55)
1–10 keV (3.03) 1–10 keV (0.30)
10–20 keV (0.42)
20–30 keV (0.18)
30–40 keV (0.39)
30–40 keV (0.72)
40–50 keV (0.23) 40–50 keV (0.05)
0–50 keV (12.4) 0–50 keV (1.11)
*x-ray
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after radionuclide therapy with high doses of 161Tb-
folate and compare its nephrotoxic profile with the
results obtained with 177Lu-folate. Histopathological
changes of the renal tissue were examined after treat-
ment with 161Tb-folate and compared to the results
obtained with 177Lu-folate. Time-dependent monitor-
ing of kidney function was performed over the whole
period of investigation by the determination of blood
plasma parameters, which are indicative for renal
damage. Moreover, renal uptake of 99mTc-DMSA was
quantified using SPECT. This has proven to be a re-
liable method to determine kidney function in mice
non-invasively after radionuclide therapy. The results
of plasma parameters and SPECT were correlated
with the data obtained from histological evaluation.
Methods
Preparation of 161Tb-folate and 177Lu-folate
The DOTA-folate conjugate (cm09), herein referred
to as “folate,” was kindly provided by Merck & Cie
(Schaffhausen, Switzerland) [17]. No-carrier-added 161Tb
was produced at the spallation-induced neutron source
(SINQ) at Paul Scherrer Institut (PSI) (Villigen-PSI,
Switzerland) or at the high-flux reactor of the Institut
Laue-Langevin (ILL, Grenoble, France) using various quan-
tities of enriched 160Gd targets. Separation of 161Tb from
the target material was carried out at PSI using cation
exchange chromatography, as previously reported [1, 7].
No-carrier-added 177Lu was purchased from Isotope
Technologies Garching (ITG GmbH, Garching,
Germany). The radionuclidic purity of 161Tb and 177Lu,
respectively, was ≥99 %. A HCl solution (0.05 M) of
161TbCl3 or
177LuCl3 (500 MBq, 100 μL) was mixed
with sodium acetate (0.5 M, pH 8, 20 μL) to obtain
a pH of ~4.5. After the addition of the folate conju-
gate (25 μL, 1 mM), the reaction mixture was incu-
bated for 10 min at 95 °C. The resulting specific
activity of the radiofolates was 20 MBq/nmol. Qual-
ity control was performed using HPLC as previously
reported [17]. Before in vivo application, the radio-
conjugate solution was diluted with phosphate buff-
ered saline (PBS) (pH 7.4) and Na-DTPA (10 μL,
5 mM, pH 5) was added for the complexation of
potential traces of unreacted 161Tb(III) or 177Lu(III).
Animal studies
The in vivo experiments were approved by the local vet-
erinarian department and conducted in accordance with
the Swiss law of animal protection. Female athymic nude
mice (Crl:CD1-Foxn1nu, 5- to 7-week-old) were pur-
chased from Charles River Laboratories (Sulzfeld,
Germany). The mice received a folate-deficient rodent
chow (ssniff Spezialdiäten GmbH, Soest, Germany),
starting 1 week prior to the injection of the radiofolates.
The folate-free diet was replaced by a standard rodent
diet (Kliba Nafag, Kaiseraugst, Switzerland) 3 weeks after
application of the radiofolates.
Dosimetry
Dosimetric calculations were performed based on biodis-
tribution data, which were previously obtained after the
injection of 161Tb-folate and 177Lu-folate (2–3 MBq/
0.5 nmol per mouse) using the same strain of mice
(Crl:CD1-Foxn1nu) [2, 17, 19]. To estimate the mean
absorbed radiation dose of 161Tb-folate and 177Lu-folate
in the renal tissue, calculations were performed as
follows: the cumulative radioactivity was calculated by
fitting a bi-exponential curve to the non-decay-
corrected biodistribution data (% IA/g). The area
under the curve (MBq∙s) was determined by integrat-
ing the bi-exponential function to infinity. The mean
absorbed dose to the kidneys was assessed for a kid-
ney mass of 125 mg, having an elliptical shape and
uniform activity distribution [20]. For the calculation
of the absorbed fraction, the Monte Carlo code PE-
NELOPE was used, resulting in an absorbed fraction
of 0.93. In the simulation, detailed simulation mode
was employed and the electron-absorption energy was
100 eV [21]. The mean absorbed dose (Gy/MBq) was
calculated by multiplying the area under the curve
normalized to 1 MBq injected activity (IA), with the
absorbed fraction and the emitted energy per decay
for 161Tb and 177Lu [3] and multiplied with a conver-
sion factor.
Long-term side effects after application of 161Tb-folate
and 177Lu-folate
Effects of 161Tb-folate and 177Lu-folate, applied to non-
tumor-bearing mice at therapeutic doses, were investi-
gated over a period of 8 months. Control mice were
intravenously (i.v.) injected with only saline (group A,
n = 9). Three groups of six mice each were i.v.
injected with 161Tb-folate of different activities (group
B: 10 MBq, 0.5 nmol folate; group C: 20 MBq, 1 nmol
folate; and group D: 30 MBq, 1.5 nmol folate). The
same activites of 177Lu-folate were i.v. injected into
three additional groups of six mice each (group E:
10 MBq, 0.5 nmol folate; group F: 20 MBq, 1 nmol
folate; and group G: 30 MBq, 1.5 nmol folate). End-
point criteria were defined as weight loss of >15 % of
the initial body weight and/or signs of unease. Body
weights were measured once a week for the determin-
ation of the relative body weight (RBW =WX/W0;
with WX = body weight at day x and W0 = body weight
at day 0) and indicated as average RBW for each
group.
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Determination of renal uptake of 99mTc-DMSA using
SPECT
The renal function of mice was monitored by the deter-
mination of the renal uptake of 99mTc-DMSA using
SPECT, as previously reported [22, 23]. DMSA (Tech-
neScan®, Mallinckrodt, Petten, The Netherlands) was
radiolabeled with 99mTc (radionuclidic purity >99.9 %),
obtained from a 99Mo/99mTc-generator (Mallinckrodt,
Petten, The Netherlands) at an activity concentration of
3 GBq in 5 mL. Quality control performed by TLC
revealed a radiochemical purity of >95 %. SPECT acqui-
sitions were performed 2 h after the injection of 99mTc-
DMSA (30-40 MBq per mouse) using a NanoSPECT/
CT™ (Mediso Medical Imaging Systems, Budapest,
Hungary) and Nucline Software (version 1.02, Bioscan
Inc., Poway, USA). For this purpose, the energy window
of 99mTc was set to 140.5 ± 14 keV. The acquired data
were reconstructed using HiSPECT software (version
1.4.3049, Scivis GmbH, Göttingen, Germany), and the
renal uptake of 99mTc-DMSA was determined, as previ-
ously reported, using the VivoQuant post-processing
software (version 1.23, inviCRO Imaging Services and
Software, Boston, USA) [19]. The determined activities
were decay-corrected and expressed as percentage of
injected activity (% IA) per kidney.
Determination of blood plasma parameters
Blood urea nitrogen and creatinine were measured in
weeks 8, 19, and 26 and at the day of euthanasia of the
mice. Blood was taken from the sublingual vein of each
mouse, collected in heparinized vials, and centrifuged.
Blood plasma samples were analyzed using a Fuji Dri-
Chem 4000i analyzer (Polymed Medical Center AG,
Glattbrugg, Switzerland).
Histological analysis
All animals were euthanized with CO2, followed by
exsanguination. The kidneys were removed and fixed
in 4 % buffered formalin (Formafix buffered 4 %,
Switzerland AG, Hittnau, Switzerland). The tissue was
trimmed, dehydrated, and embedded in paraffin wax.
Sections of 3–5 μm thickness were prepared,
mounted on glass slides, deparaffinized in xylene, and
rehydrated through graded alcohols, before staining
with hematoxylin and eosin (HE) for the histological
examination. Renal injury was assessed by light mi-
croscopy. Glomerular, tubular, and interstitial lesions
were evaluated separately using pre-defined criteria
(Table 2), adapted from previously published studies
[19, 24]. The values obtained for each compartment
were summed to obtain a cumulative score. The cu-
mulative score was then converted to a final score
ranging from 0 to 5 (Table 3). No damage (score 0)
indicated normal histology, while variably severe renal
injury ranged from minimal damage (score 1), char-
acterized by mildly reduced numbers of capillaries
within the glomerular tuft and patchy tubular col-
lapse, to severe renal damage (score 5), dominated by
widespread glomerulosclerosis and prominent cortical
Table 2 Histological partial scoring, with each compartment
(glomeruli, tubules, interstitium) evaluated separately
Partial score Pathological changes
1 Glomeruli: mild deposition of PTAH-positive
eosinophilic material (fibrin) and reduced
number of capillaries in a few glomeruli.
Tubules: <10 % of cortical tubules collapsed or
degenerated.
Interstitium: few small mononuclear cell infiltrates
and/or minimal fibrosis in the cortex.
2 Glomeruli: mild/moderate fibrin deposition and
reduced number of capillaries in numerous glomeruli.
Tubules: 10–25 % of cortical tubules collapsed or
degenerated.
Interstitium: multifocal small mononuclear cell
infiltrates and/or mild fibrosis in the cortex.
3 Glomeruli: marked fibrin deposition and reduced
number of capillaries in numerous glomeruli.
Tubules: 25–50 % of cortical tubules collapsed or
degenerated.
Interstitium: multifocal larger mononuclear cell
infiltrates and/or moderate fibrosis in the cortex.
4 Glomeruli: marked fibrin deposition and reduced
number of capillaries in numerous glomeruli;
glomerulosclerosis in a few to several glomeruli.
Tubules: 50–75 % of cortical tubules collapsed or
degenerated; numerous dilated tubules.
Interstitium: multifocal larger mononuclear cell
infiltrates and/or moderate fibrosis in the cortex
and medulla; mild/moderate parenchymal collapse.
5 Glomeruli: majority of glomeruli sclerotic.
Tubules: >75 % of cortical tubules collapsed or
degenerated; numerous dilated tubules.
Interstitium: severe parenchymal collapse, affecting
cortex and medulla.
Table 3 The partial scoring of each compartment (glomeruli,
tubules, and interstitium) was summed to obtain the cumulative
score
Cumulative score (glomeruli,
tubules, interstitium)
Final score Renal injury
0–0.9 0 No histological abnormality
1.0–2.9 1 Minimal
3.0–6.9 2 Mild
7.0–10.9 3 Moderate
11.0–13.9 4 Marked
14.0–15.0 5 Severe
The cumulative score was then converted to a final score indicating the
degree of renal injury
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parenchymal shrinkage. A phosphotungstic acid-
hematoxylin (PTAH) staining was performed on
tissues of selected mice for the identification of fibrin.
Statistical analysis
Data are presented as mean ± standard deviation. Statis-
tics were conducted by using one-way ANOVA with
Bonferroni’s multiple comparison post-test (GraphPad
Prism, version 5.01).
Results
Radiolabeling
The radiolabeling of the folic acid conjugate was suc-
cessfully achieved with 161Tb and 177Lu, respectively, at
a specific activity of 20 MBq/nmol. Quality control per-
formed by HPLC revealed a radiochemical yield >97 %.
Dosimetric calculations
The mean absorbed kidney dose was estimated at
3.0 Gy/MBq for 161Tb-folate, of which ~76 % (2.3 Gy/
MBq) was due to the β−-particles and ~24 % (0.7 Gy/
MBq) due to Auger/conversion electrons. For 177Lu-folate,
the total absorbed dose was estimated at 2.3 Gy/MBq,
caused primarily by β−-particles, with only <1 % being
due to Auger/conversion electrons (Table 4).
Body weight and survival
All mice gained weight over the first month of the ex-
periment, as a consequence of normal growth. Mice
which were injected with 10 or 20 MBq of 161Tb-folate
and 177Lu-folate, respectively, showed body weight gain
within the first 6 weeks, followed by stabilization of the
body weight in the range of 1.1 to 1.3 RBW (Fig. 1a).
The majority of these mice (>50 %), as well as the con-
trol mice (groups A, B, C, E, and F), survived until the
end of the study in week 34, and consequently, the sur-
vival time remained undefined (Fig. 1b). Four mice in
these groups had to be euthanized in weeks 14, 19, 28,
and 32, respectively, due to end-point criteria being
reached, however. Mice that received high activities
(30 MBq) of 161Tb-folate (group D) and 177Lu-folate
(group G), respectively, lost body weight from week 15
on and showed signs of unease. This prompted eu-
thanasia, in most of the cases, between weeks 15 and
26. The median survival time of 161Tb-folate treated
mice (group D) was 17 weeks, whereas for 177Lu-fol-
ate treated mice (group G), the median survival was
23.5 weeks (Fig. 1b). This difference was determined
not to be significant.
Renal uptake of 99mTc-DMSA
When the study reached week 3, all treated mice showed
comparable renal uptake of 99mTc-DMSA, which was in
the same range as for the control mice of group A (data
not shown). The mice injected with low activities of
161Tb-folate (group B; 10 MBq) and 177Lu-folate (group
E; 10 MBq), respectively, showed reduced 99mTc-DMSA
uptake only 30 weeks after radiofolate injection, whereas
no significant deviation from controls was observed at
earlier time points (Fig. 2). In mice which were treated
with 20 MBq of 161Tb-folate and 177Lu-folate, respect-
ively, the uptake of 99mTc-DMSA was 7.6 ± 0.5 % IA/kid-
ney (group C) and 8.5 ± 1.2 % IA/kidney (group F) in
week 15 and, thus, slightly lower than the value obtained
for control mice (11 ± 1.8 % IA/kidney). In these mice
(groups C and F), renal uptake of 99mTc-DMSA de-
creased further in week 22 and week 30 (Fig. 2). The re-
duction of 99mTc-DMSA was, however, comparable in
mice injected with 161Tb-folate and 177Lu-folate (10 and
20 MBq), respectively.
Mice injected with the highest activity of 161Tb-folate
(group D; 30 MBq) and 177Lu-folate (group G; 30 MBq)
showed a significantly reduced renal uptake of 99mTc-
DMSA when compared to controls (group A) already in
week 15 (Fig. 2). The determination of 99mTc-DMSA up-
take in week 15 revealed a significantly reduced value
for mice injected with 30 MBq 161Tb-folate, compared
to mice, which received 30 MBq 177Lu-folate. At later
time points, the obtained values were, however, always
comparable between these mice (groups D and G).
Renal plasma parameters
Values of blood urea nitrogen and creatinine were not
significantly different for control mice and mice treated
with 10 MBq 161Tb-folate (groups B) over the entire
period of investigation (Table 5). Mice which received
20 MBq 161Tb-folate (group C) showed slightly, but not
significantly, increased levels of blood urea nitrogen as
compared to control mice from week 26 on. Animals
that received higher activities of 161Tb-folate (30 MBq,
group D), however, showed significantly increased levels
of blood urea nitrogen at terminal bleeding (42 ±
8.1 mM (n = 4) and > 50 mM (n = 2)) as compared to
control mice (group A: 8.4 ± 1.4 mM). In the 177Lu-fol-
ate-treated groups, increasing levels of blood urea nitro-
gen were also observed in mice injected with 30 MBq
(>50 mM). Moreover, significantly increased levels of
blood urea nitrogen were also determined at terminal
Table 4 Estimated mean absorbed kidney doses in mice after
injection of 161Tb-folate and 177Lu-folate
Control 161Tb-folate 177Lu-folate
Group A B C D E F G
Injected activity (MBq) 0 10 20 30 10 20 30
Mean absorbed kidney dose (Gy) 0 30 60 90 23 46 68
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stage in mice that received only 20 MBq of 177Lu-folate
(group G: 38 ± 4.1 mM; Table 5).
Application of high activities of 161Tb-folate (group D,
30 MBq) resulted in a significant increase of creatinine
plasma levels (77 ± 17 μM), as compared to control mice
of group A (24 ± 5.1 μM (n = 6), <18 μM (n = 3)) at ter-
minal state and the same observation (creatinine level of
107 ± 35 μM) was also made for 177Lu-folate treated
mice (group G, 30 MBq). In mice which received
20 MBq 161Tb-folate (group C) and 177Lu-folate
(group F), respectively, slightly, but not significantly,
increased levels of creatinine were determined in
Week 26 and at terminal bleeding.
Renal histopathology
The application of 161Tb-folate and 177Lu-folate re-
sulted in a dose-dependent renal damage consistent
with radiation nephropathy (Table 6). The kidneys of
the control animals did not show histological abnor-
mality and received a final score of 0. The renal tis-
sue of mice injected with increasing activities of
radiofolates showed progressively more severe kidney
damage, which was graded with final scores between
1 and 5 (Fig. 3). For the mice treated with 161Tb-fol-
ate, final scores of 1 (group B, 10 MBq), 3 (group C,
20 MBq), and 4 (group D, 30 MBq) were determined.
In the case of 177Lu-folate application, renal damage
was scored with 2 (group E, 10 MBq), 3 (group F,
20 MBq), and 4 (group G, 30 MBq). Lower scores
were characterized by localized tubular collapse, high
proportions of viable tubules, and enlarged glomeruli
with reduced numbers of capillaries. These changes
became more prominent in the severely injured kid-
neys, where occasional to frequent glomerulosclerosis
was also observed (Fig. 3). Moreover, a gradual thin-
ning of the cortex with increasing amounts of applied
radiofolate was observed during the investigation of
renal cross sections (Fig. 3).
Correlation of kidney function tests and renal
histopathology
Retrospectively, renal function parameters determined
shortly before euthanasia were correlated with the hist-
ology scores on an individual basis (Fig. 4). Increasing
blood urea nitrogen levels correlated (r2 = 0.87) well with
rising scores of radiation nephropathy (Fig. 4a). The cre-
atinine levels indicated, however, only a slight trend in
the same direction as they showed poor correlation with
the scoring results (r2 = 0.52). A relatively good correlation
(r2 = 0.68) was found between the determination of renal
damage using 99mTc-DMSA/SPECT and the overall score
determined by histopathological evaluation of the renal
damage.
Fig. 1 Average relative body weights (RBW) (a) and median survival (b) of mice from each group after the injection of different activities of
161Tb-folate and 177Lu-folate, respectively. RBWs are shown for each group for the time when at least two mice were alive (n ≥ 2)
Fig. 2 SPECT-based quantification of renal 99mTc-DMSA uptake (% IA) in Week 15 (a), 22 (b), and 30 (c) after injection of 161Tb- and 177Lu-folate.
*P < 0.05, **P < 0.01, ***P < 0.001
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Discussion
A cumulative renal dose of >25 Gy as a result of 177Lu-
or 90Y-based radionuclide therapy comprises a high risk
of renal damage in patients [25]. In contrast, radio-
nuclide therapy based on Auger/conversion electrons
using 111In-octreotide did not impair kidney function up
to a renal dose of 45 Gy [26]. It was hypothesized that,
because of their short tissue range, Auger/conversion
electrons are unable to damage the radiosensitive glom-
eruli and potential cell damage would, therefore, be lim-
ited to the more radioresistant tubular cells, in which
the radioconjugates accumulate [26]. Thus, it was specu-
lated that the accumulation of activity into specific organ
structures, yielding a local energy deposit for short-
ranged electrons, might be the reason for the reduced
impairment of renal function after therapy with short-
ranged Auger/conversion electrons, as compared to
treatment with the long-ranged β−-particles.
In this work, we investigated potential radionephro-
toxicity caused by therapeutic doses of 161Tb-folate in
mice. The data were compared with those previously
obtained with 177Lu-folate [19]. The slightly higher β−-
energy of 161Tb (Eβ−av = 154 keV) compared to
177Lu
(Eβ−av = 134 keV) and, predominantly, the co-emitted
Auger/conversion electrons of 161Tb resulted in about
1.3-fold increased mean absorbed kidney dose (3.0 vs.
2.3 Gy/MBq), if the same activities of 161Tb-folate
and 177Lu-folate were employed. The Auger/conversion
Table 5 Blood urea nitrogen and creatinine levels in blood plasma of mice injected with 161Tb-folate or 177Lu-folate
Control 161Tb-folate 177Lu-folate
Week Group A Group B: 10 MBq Group C: 20 MBq Group D: 30 MBq Group E: 10 MBq Group F: 20 MBq Group G: 30 MBq
Blood urea nitrogen (mM)
8 8.8 ± 0.8 (n = 7) 9.0 ± 1.3 (n = 5) 8.6 ± 0.6 (n = 6) 14 ± 7.5* (n = 6) 11 ± 0.8 (n = 6) 8.3 ± 0.6 (n = 6) 8.8 ± 0.6 (n = 4)
19 9.8 ± 0.6 (n = 9) 9.4 ± 0.6 (n = 6) 11 ± 1.6 (n = 5) 23 (n = 1) 10 ± 0.7 (n = 6) 9.3 ± 2.5 (n = 6) 26 ± 13*** (n = 6)
26 8.5 ± 0.8 (n = 9) 8.6 ± 1.6 (n = 6) 16 ± 12 (n = 5) n.d. 9.2 ± 0.5 (n = 5) 21 ± 7.2 (n = 5) >50*** (n = 1)
Terminal 8.4 ± 1.4 (n = 9) 9.2 ± 3.0 (n = 6) >50 (n = 1) >50 (n = 2) 10 ± 2.6 (n = 5) 38 ± 4.1*** (n = 4) >50*** (n = 5)
13 ± 3.2 (n = 5) 42 ± 8.1*** (n = 4)
Creatinine (μM)
8 <18 (n = 3) <18 (n = 3) <18 (n = 6) <18 (n = 1) <18 (n = 3) <18 (n = 3) <18 (n = 4)
21 ± 3.5 (n = 4) 32 ± 1.4 (n = 2) 31 ± 14 (n = 5) 20 ± 1.0 (n = 3) 18 (n = 1)
19 26 ± 9.6 (n = 8) <18 (n = 2) <18 (n = 3) 32 (n = 1) <18 (n = 3) <18 (n = 2) 25 ± 6.3 (n = 6)
25 ± 7.3 (n = 4) 21 ± 4.9 (n = 2) 22 ± 0.6 (n = 3) 18 ± 0 (n = 3)
26 <18 (n = 4) <18 (n = 4) <18 (n = 2) n.d. 30 ± 19 (n = 5) 33 ± 7.6 (n = 5) 46 (n = 1)
20 ± 1.7 (n = 4) 22 ± 0.7 (n = 2) 33 ± 5.9 (n = 3)
Terminal <18 (n = 3) 21 ± 3.8 (n = 6) <18 (n = 1) 77 ± 17* (n = 6) 25 ± 7.6 (n = 5) <18 (n = 2) 107 ± 35** (n = 5)
24 ± 5.1 (n = 6) 51 ± 48 (n = 5) 63 ± 46 (n = 2)
The blood plasma parameters were determined in Week 8, 19, 26 and before euthanasia (terminal)
Abbreviations: n.d. not determined (already euthanized), n number of mice
Statistics: comparison of treated animals to control; *P < 0.05, **P < 0.01, ***P < 0.001
Detection limits: blood urea nitrogen: 50 mM; creatinine: 18 μM
Table 6 Histological evaluation of renal radiation injury in mice injected with 161Tb-folate or 177Lu-folate, indicated with partial
scores for glomeruli, tubules, and interstitium
Control 161Tb-folate 177Lu-folate
Group Aa
(n = 9)
Group B: 10 MBq Group C: 20 MBq Group D: 30 MBq Group E: 10 MBq Group F: 20 MBq Group G:30 MBq
(n = 5)a (n = 5)a (n = 2)b (n = 5)a (n = 4)a (n = 5)b
Glomeruli 0 1.1 3.4 5.0 2.0 3.8 5.0
Tubules 0 0.9 2.4 4.5 1.5 3.3 4.2
Interstitium 0 0.4 1.8 4.0 0.4 3.3 4.6
Cumulative score 0 2.4 7.6 13.5 3.9 10.4 13.8
Final score 0 1 3 4 2 3 4
The sum of the partial scores determined the cumulative scores, which were then converted to the final score as a measure for the different degrees of renal
injury
aMice euthanized in Week 34
bMice euthanized between Weeks 15 and 26
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electrons contributed with about 24 % of the mean
absorbed renal dose upon the injection of 161Tb-folate. In
this experimental setting, the applied mean absorbed renal
dose of 161Tb-folate ranged from 30 Gy (10 MBq) to
90 Gy (30 MBq). The corresponding dose for 177Lu-folate,
applied at the same activity, ranged from 23 Gy (10 MBq),
as the safe limit, to 68 Gy (30 MBq), which is known
to induce renal damage [19]. The absorbed doses that
are presented refer to the whole mean absorbed kid-
ney dose, as it is most often presented in clinical
studies [10]. Furthermore, an even more detailed
description of the activity deposited into the proximal
tubular cells might differentiate the absorbed dose
profiles for 161Tb and 177Lu due to different emission
of low-energy electrons. A detailed nephron-based
model of the absorbed dose to the kidneys has re-
cently been described by Hobbs et al. for α-emitters
[27]. A similar approach will be utilized in the future
for the characterization of the absorbed dose profiles
for 161Tb and 177Lu, together with detailed autora-
diography studies at different time points after
injection.
Fig. 3 Histology (HE staining) of radiation-induced nephropathy in mice. Representative histological images (×20 magnification) of kidneys from
untreated controls (final score 0) and progressively severe kidney damage (final scores 1–5) from mice injected with different activities of
161Tb-folate (▲ = localized tubular collapse; v = viable tubules; Δ = enlarged glomeruli with reduced numbers of capillaries;→ = glomerulosclerosis).
In the insets, cross sections of the kidneys are presented (×2 magnification) indicating gradual thinning of the cortex (↔) with increasing scores
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The injection of high activities of 161Tb-folate
(30 MBq), which resulted in a mean absorbed kidney
dose of 90 Gy (and as discussed above, might be 1.5-fold
higher, if all activity is considered to be located in the
cortex), was not well tolerated and resulted in body
weight loss, which required euthanasia in the second
half of the study (Fig. 1). End-point criteria were reached
earlier in 161Tb-folate treated mice (group D) than in
mice which received the same activities of 177Lu-folate
(30 MBq, ~68 Gy, group G). The severity of renal dam-
age, assessed by kidney function tests and histological
evaluation, was, however, comparable between mice
injected with 161Tb-folate (group D) and 177Lu-folate
(group G). The reason why the relative body weight and
survival rate did not correlate well with the severity of
renal damage in these high-dose treatment groups
remains unknown and might involve other factors refer-
ring to global toxicity, which were not investigated in
this study.
99mTc-DMSA uptake studies performed 3 weeks after
radiofolate application showed comparable results in all
groups indicating normal kidney function. In Week 15,
impaired kidney function was observed in mice which
were exposed to 20 and 30 MBq of 161Tb-folate or
30 MBq of 177Lu-folate (groups C, D, and G) based on
the results obtained with 99mTc-DMSA (Fig. 2a). About
7 months after radiofolate treatment, the mice which
were exposed to lower renal doses (groups B, E, and F)
also showed a significantly reduced uptake of 99mTc-
DMSA in comparison to untreated control mice (Fig. 2c).
Parallel analyses of blood urea nitrogen and creatinine
plasma levels confirmed the dose-dependent impair-
ment of kidney function which was observed in stud-
ies with 99mTc-DMSA-based SPECT.
The same activity of 161Tb-folate and 177Lu-folate did
not cause significant differences regarding renal uptake
of 99mTc-DMSA and rising levels of plasma parameters,
indicative for kidney function, over the whole period of
investigation. This observation indicates that the impair-
ment of renal function runs in parallel for 161Tb-folate
and 177Lu-folate. A significantly lower renal accumula-
tion of 99mTc-DMSA was only found in week 15 for
mice treated with 30 MBq 161Tb-folate (Group D) com-
pared to mice injected with 30 MBq 177Lu-folate (Group
G). Other than that, the determination of blood urea ni-
trogen and creatinine plasma levels did not confirm a
significant difference of the renal function in mice of
groups D and G at any time of the study. In contrast, at
terminal state, there was even a tendency of increased
blood urea nitrogen and creatinine levels in 177Lu-folate-
treated mice (Group G) as compared to the levels deter-
mined in 161Tb-folate-treated mice (Group D).
Histopathological changes were investigated with renal
tissue of euthanized mice, when an end-point criterion
was reached or after termination of the study in Week
34. A reduced renal mass and thinning of the renal cor-
tex was observed along with increasing tissue damage in
the renal cortex, where radiofolates accumulate because
of FR-expression in the proximal tubular cells [11, 18].
Evaluation of the partial and cumulative scores in the
tubules, glomeruli, and interstitium showed equal distri-
bution and location of renal damage independent on the
radionuclide which was employed (Table 6). This means
Fig. 4 Correlation of individual results for kidney function tests and
histological scores of the corresponding renal tissue sample.
a Correlation of the histological scores and terminal blood urea
nitrogen levels; b Correlation of the histological scores and terminal
creatinine levels; c Inverse correlation of the histological scores and
99mTc-DMSA uptake in the kidneys
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that the application of 161Tb-folate resulted in renal
damage that was comparable to that observed after the
application of 177Lu-folate at the same activity, in spite
of the 1.3-fold higher dose which was deposited in the
case of 161Tb-folate. These data are in line with the
hypothesis that the additional dose of 161Tb-folate, due
to Auger/conversion electrons, has no adverse effect on
renal function and morphology. This theory appears
plausible for radiopharmaceuticals that accumulate
primarily in tubular cells, as it is the case for folate-
and peptide-based radioconjugates [18, 28–30]. Auger/
conversion electrons deposit energy over subcellular
dimensions only and, hence, no other parts of the kidneys
will be reached other than the tubules. Our observation is
in agreement with the theory that in the case of kidneys
which is defined as flexible tissue (in contrast to hie-
rarchical tissues [31]), the irradiated volume and affected
suborgan unit are critical factors for the final renal
injury [32, 33].
The above reported results are corroborated by the
fact that values determined for blood urea nitrogen
levels correlated well with the histopathological analysis
which was performed in an independent setting (Fig. 4).
The value of creatinine levels for predicting renal dam-
age appears to be questionable due to high variability
and poor correlation with the histopathological changes.
The unreliable value of creatinine as an indicator for
renal damage was previously reported in the literature
[34]. From a methodological point of view, 99mTc-
DMSA/SPECT is undoubtedly the most sensitive
method for non-invasive monitoring of renal function.
Conclusions
The functional and histopathological analysis of the kid-
neys after application of 161Tb-folate revealed a dose-
dependent damage which was comparable to the damage
caused by 177Lu-folate applied using the same activity.
These observations are in line with the hypothesis that
Auger electrons and low energy conversion electrons do
not result in additional renal injury, as previously ob-
served during therapeutic application of 111In-octreotide
in patients. The confirmation of these results, in more
detailed future studies, will support the clinical applica-
tion of 161Tb-based therapy, which could contribute to
increase the success rate of the treatment without caus-
ing additional renal side effects.
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